Bloomberg Masters in Business: Stephanie Kelton
Barry speaks with Stephanie Kelton, Professor of Economics and Public Policy at Stony Brook University and Senior Fellow at the Schwartz Center for Economic Policy Analysis. Previously, Professor Kelton was Chair of the Department of Economics at the University of Missouri, Kansas City. In addition to her work in academia, Stephanie has held numerous roles in the political sphere. She served as chief economist on the U.S. Senate Budget Committee, and was senior economic adviser for Bernie Sanders' 2016 and 2020 presidential campaigns. She has made virtually all the 'top 50 lists' including POLITICO's 50 Most Influential Thinkers in 2016 and Bloomberg Businessweek's 50 People Who Defined 2019. She was also named to Barron's 100 Most Influential Women in Finance. She has held several visiting professorships and has written for publications such as the Financial Times, The New York Times, CNN, and more. On this episode, Barry and Stephanie discuss US fiscal policy, recession risks, and her New York Times bestseller The Deficit Myth: Modern Monetary Theory and the Birth of the People's Economy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Flow Cytometry in Oncology and Immunology Market Research 2025 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F
Opportunities in the Flow Cytometry in Oncology and Immunology Market include increasing global demand for precision diagnostics driven by cancer incidence and the rise of immuno-oncology. The integration of AI/ML enhances data analysis, expanding flow cytometry's role in personalized treatment and diagnostics across the globe. Flow Cytometry in Oncology and Immunology Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. The Flow Cytometry in Oncology and Immunology Market was valued at USD 3.41 Billion in 2024, and is expected to reach USD 5.47 Billion by 2030, rising at a CAGR of 8.19% Market growth is propelled by the increasing utility of flow cytometry in cancer and immunology research, alongside the evolution of advanced flow cytometers. With cancer ranking among the leading causes of death globally, and immuno-oncology gaining ground as a crucial discipline, there is rising demand for high-precision diagnostic and monitoring tools. Flow cytometry has become indispensable in evaluating cell characteristics, immune markers, and tumor antigens across various sample types. The integration of next-generation flow cytometry tools with therapeutic monitoring and diagnostics, especially in clinical trials for immunotherapies and personalized treatments, is boosting global adoption. Combined with rising research investments and the global emphasis on early disease detection, these factors are collectively expanding the reach and application of flow cytometry in both oncology and immunology. Key Market Drivers: Rising Cancer Incidence Driving Diagnostic Demand: The growing global cancer burden is a key driver for the adoption of flow cytometry in oncology diagnostics. This technique is critical for diagnosing and monitoring blood cancers like leukemia and lymphoma, enabling precise cellular analysis and biomarker identification. As per WHO, cancer accounted for nearly 10 million deaths in 2020, and GLOBOCAN estimates that new cancer cases will surge past 28 million by 2040. Flow cytometry is also instrumental in detecting minimal residual disease (MRD) and supporting treatment decisions. With increasing adoption of immunotherapies and personalized oncology treatments, flow cytometry's role in immune profiling and response monitoring is expanding. In support, organizations like the U.S. National Cancer Institute have committed billions to precision medicine and diagnostics infrastructure, fostering widespread implementation. These efforts underscore flow cytometry's importance in the future of cancer diagnosis and treatment. Key Market Challenges: High Cost and Operational Complexity: Despite its clinical and research value, flow cytometry adoption is hindered by high operational and capital expenses. The cost of acquiring high-end instruments, software, and consumables is substantial, making it challenging for institutions in developing regions to invest. Additionally, flow cytometry requires technical expertise for calibration, analysis, and interpretation - skills that are often limited in resource-constrained settings. Complex data interpretation can introduce variability and errors, further complicating implementation. The lack of infrastructure and diagnostic capacity in many low- and middle-income countries reinforces disparities in access to this technology. According to WHO data, these regions have significantly fewer diagnostic labs per capita, highlighting access challenges. Addressing these cost and skill barriers is essential to ensuring broader and more equitable utilization of flow cytometry worldwide. Key Market Trends: Integration with Artificial Intelligence and Machine Learning: A transformative trend in the flow cytometry space is the integration of artificial intelligence (AI) and machine learning (ML) into data processing workflows. Traditional manual gating and analysis can be time-consuming and prone to human error. AI and ML technologies now streamline these processes by automating gating, improving pattern recognition, and extracting high-dimensional insights from complex datasets. In oncology, ML algorithms are being applied to predict treatment outcomes using immune signatures from flow cytometry data. In immunology, these tools aid in identifying rare cell subsets and monitoring immune dynamics with high precision. Global research initiatives like NIH's Bridge2AI and the EU's Horizon Europe are actively funding the incorporation of AI into diagnostics, including flow cytometry. This convergence of data science with laboratory medicine is poised to elevate accuracy, reproducibility, and clinical utility, marking a pivotal evolution in how flow cytometry is applied in healthcare. Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.41 Billion Forecasted Market Value (USD) by 2030 $5.47 Billion Compound Annual Growth Rate 8.1% Regions Covered Global Report Scope Key Market Players: Danaher Corporation Merck KGaA Miltenyi Biotec Neo-Genomics Laboratories, Inc. Thermo Fisher Scientific Inc. Cell Signaling Technology, Inc. Becton, Dickinson and Company Agilent Technologies, Inc. DiaSorin S.p.A OPKO Health, Inc. Flow Cytometry in Oncology and Immunology Market, By Type: Immunology Oncology Flow Cytometry in Oncology and Immunology Market, By Technology: Cell-based flow cytometry Bead-based flow cytometry Flow Cytometry in Oncology and Immunology Market, By Offering: Reagents Instruments Consumables Software Flow Cytometry in Oncology and Immunology Market, By Application: Translational Research Clinical Research Flow Cytometry in Oncology and Immunology Market, By End User: Hospitals Diagnostic Laboratories Reference Laboratories Pharmaceutical and Biotechnology Companies Academic Research Institutes Contract Research Organizations Others Flow Cytometry in Oncology and Immunology Market, By Region: North America United States Mexico Canada Europe France Germany United Kingdom Italy Spain Asia-Pacific China India South Korea Japan Australia South America Brazil Argentina Colombia Middle East and Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Flow Cytometry in Oncology and Immunology Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Yahoo
Tuberculosis Therapeutics Market Opportunity, and Forecasts Report 2025-2030: Next-Gen Drug Development Demands, Cost Efficiency, Regulatory Agility, and Strategic Partnerships Influence on Growth
The Tuberculosis Therapeutics Market is driven by rising drug-resistant TB and persistent global demand. Opportunities include developing innovative, cost-effective TB drugs with shorter, more effective regimens. Companies can gain a competitive edge through strategic collaborations and navigating regulatory barriers. Tuberculosis Therapeutics Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Tuberculosis Therapeutics Market was valued at USD 2.18 Billion in 2024, and is expected to reach USD 2.94 Billion by 2030, rising at a CAGR of 5.05% Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development - particularly in second-line therapies - on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge. Key Market Drivers High Global Burden of TuberculosisThe global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial Market Challenges Inadequate Funding and Limited Commercial Incentives for Drug DevelopmentThe concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical Market Trends Shift Toward Shorter, More Effective Treatment RegimensThere is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.18 Billion Forecasted Market Value (USD) by 2030 $2.94 Billion Compound Annual Growth Rate 5.0% Regions Covered Global Report Scope Key Market Players AstraZeneca PLC Johnson & Johnson Services, Inc. Eli Lilly and Company Mylan Inc. Teva Pharmaceutical Industries Ltd Sanofi Novartis AG Sun Pharmaceutical Industries Ltd Pfizer Inc. Tuberculosis Therapeutics Market, By Disease Type: Active TB Latent TB Tuberculosis Therapeutics Market, By Therapy: First-Line Therapy Second-Line Therapy Tuberculosis Therapeutics Market, By Route of Administration: Oral Parenteral Others Tuberculosis Therapeutics Market, By Dosage Form: Tablets Capsules Injection Others Tuberculosis Therapeutics Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Tuberculosis Therapeutics Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Tuberculosis Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 days ago
- Yahoo
Bioelectronic Medicine Market Research Report 2025 Featuring Key Players - Medtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl
The bioelectronic medicine market is expanding due to increased demand for advanced treatments for chronic diseases and the aging population, driven by governmental support and tech integration. Challenges include high costs and reimbursement issues, while AI and digital health innovations present significant growth opportunities. Bioelectronic Medicine Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Bioelectronic Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. The Bioelectronic Medicine Market was valued at USD 23.54 Billion in 2024, and is expected to reach USD 33.59 Billion by 2030, rising at a CAGR of 6.10% Market growth is being driven by rising demand for advanced healthcare solutions for chronic illnesses such as cardiovascular and neurological disorders. Increasing governmental support and investments in the development of bioelectronic therapies are boosting global adoption. Additionally, with greater integration of technology in healthcare, the use of devices like pacemakers and defibrillators is becoming more widespread. The growing awareness of the benefits associated with these devices - such as reduced side effects and improved patient outcomes - further accelerates demand. These factors, coupled with rising disposable incomes and a growing aging population, are expected to sustain the upward trajectory of the bioelectronic medicine market globally. Rising Prevalence of Chronic Diseases and Aging Population The increasing global burden of chronic diseases - such as cardiovascular ailments, diabetes, and neurological disorders - is significantly contributing to the expansion of the bioelectronic medicine market. These long-term conditions often require continuous and targeted treatment approaches. Bioelectronic medicine, which includes technologies like pacemakers and neurostimulators, offers precise and less invasive alternatives to conventional pharmaceuticals. According to WHO, cardiovascular diseases account for nearly 17.9 million deaths annually, making them the leading cause of mortality worldwide. Similarly, the International Diabetes Federation estimated that 537 million adults lived with diabetes in 2021 - a figure projected to grow to 643 million by 2030. This trend is further compounded by global demographic shifts, with one in six individuals expected to be over 65 by 2050. These factors collectively emphasize the need for reliable and innovative bioelectronic interventions, especially among elderly populations who are more vulnerable to chronic illnesses and adverse drug reactions. High Costs and Limited Reimbursement Policies Despite its therapeutic potential, the bioelectronic medicine market faces challenges related to the high cost of devices and limited reimbursement coverage. Advanced implantable devices such as neurostimulators and defibrillators involve complex manufacturing processes and high R&D investments, resulting in substantial costs. In low- and middle-income countries, these high prices often place such treatments out of reach for a significant portion of the population. Furthermore, reimbursement frameworks for bioelectronic therapies are inconsistent across regions. In many cases, insurance does not fully cover the cost of treatment, making it financially burdensome for patients. WHO data shows that out-of-pocket medical expenses push approximately 100 million people into extreme poverty every year. These economic constraints hinder wider adoption and market penetration of bioelectronic medical solutions, especially in developing healthcare systems. Integration with Digital Health and Artificial Intelligence A major trend shaping the bioelectronic medicine market is the integration of digital health technologies and artificial intelligence (AI). AI is enhancing the precision and effectiveness of bioelectronic therapies by enabling real-time analysis of patient data and supporting personalized treatment protocols. Wearable bioelectronic devices are increasingly being used for continuous health monitoring, allowing for early intervention and proactive care. Government bodies are actively promoting these digital advancements. For example, the U.S. Department of Health and Human Services supports the adoption of AI in healthcare to improve efficiency and patient outcomes. Similarly, the European Commission's strategy for digital health encourages the implementation of smart medical technologies. The convergence of AI, data analytics, and bioelectronic medicine is paving the way for next-generation diagnostics and therapeutics, while also facilitating remote care and expanding access to treatment. Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $23.54 Billion Forecasted Market Value (USD) by 2030 $33.59 Billion Compound Annual Growth Rate 6.1% Regions Covered Global Report Scope Key Market Players: Medtronic plc Abbott Laboratories Boston Scientific Corporation Cochlear Ltd. LivaNova PLC Soterix Medical Inc. Bioinduction Ltd. GiMer Medical CEFALY BioControl Medical Bioelectronic Medicine Market, By Type: Implantable Non-invasive Bioelectronic Medicine Market, By Product: Implantable cardioverter defibrillators Cardiac pacemakers Cochlear implants Spinal cord stimulators Deep brain stimulators Transcutaneous electrical nerve stimulators Sacral nerve stimulators Vagus nerve stimulators Others Bioelectronic Medicine Market, By Application: Arrhythmia Pain management Sensorineural hearing loss Parkinson's disease Tremor Depression Treatment-resistant depression Epilepsy Urinary and fecal incontinence Others Bioelectronic Medicine Market, By End User: Hospitals Individual Users Homecare Centers Ambulatory Surgical Centers Specialty Clinics Others Bioelectronic Medicine Market, By Region: North America United States Mexico Canada Europe France Germany United Kingdom Italy Spain Asia-Pacific China India South Korea Japan Australia South America Brazil Argentina Colombia Middle East and Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Bioelectronic Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
